Field Trip will join the Nasdaq exchange on 29 July and become the first psychedelic company to list on Nasdaq’s

COVID-19 and the ‘new normal’ for healthcare provision Pioneers and early movers in the psychedelics industry are using tech to

At the start of July, US President Joe Biden signed an executive order to drive down prescription drug prices, with

Big data has revolutionised healthcare, enhancing treatment safety, efficacy and operational efficiency. The technology has become crucial to accelerate drug

At the end of June, COMPASS Pathways announced it had administered its patented psilocybin-derivative, COMP360, to 216 patients in the largest psilocybin assisted-therapy trial

Emerging themes from the Psych Symposium @ Prohibition Partners Live, 22 and 23 June 2020. What if there was a

This year’s PSYCH Investor Summit: Research & Development presents investors with the opportunity to examine Tryp Therapeutics, a publicly traded pharmaceutical company that

As the excitement builds around the FDA’s potential support of psilocybin-based drugs, ketamine-derived medicines have largely flown under the radar, despite

Following the success of the inaugural PSYCH Investor Summit: Europe and Asia on 21 April, the industry-leading global event series returns to

Today, Canadian-based biotechnology company Awakn Life Sciences began trading on the NEO Exchange under the symbol AWKN. The company’s focus is